Please login to the form below

Rybelsus

This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Also within Novo’s roster is an oral formulation of semaglutide – marketed under the Rybelsus brand name – that is authorised for the treatment of type 2 diabetes.

Latest news

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide). ... Novo won US Food and Drug Administration (FDA) approval for
Lilly’s Trulicity scores CV reduction indication in the US

Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto Securities have suggested that demand for an oral alternative GLP-1 could make the drug a $5.4bn
New drugs drive Novo Nordisk despite insulin price pressures

Novo also reported sales of DKK50m for its recently launched oral semaglutide product Rybelsus in the quarter – the company has said it is encouraged by the early performance of the drug, ... The Rybelsus launch in the US is off to a good start, and
Givlaari, Rybelsus lead crowded CHMP recommendations

Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide. ... In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved
Novo Nordisk gets MACE prevention claim for Ozempic in US

Otherwise, it is also conducting a dedicated cardiovascular outcomes trial for Rybelsus – SOUL – that is due to generate data in 2024. ... Some market predictors think Rybelsus could go even higher if the SOUL data is competitive.

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest Intelligence

On our best behaviour

Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
Cortellis Drugs to Watch in 2020 report

7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...